{"id":"https://openalex.org/W1940324115","doi":"https://doi.org/10.2147/dddt.s52787","title":"Dacomitinib in lung cancer: a \u201clost generation\u201d EGFR tyrosine-kinase inhibitor from a bygone era?","display_name":"Dacomitinib in lung cancer: a \u201clost generation\u201d EGFR tyrosine-kinase inhibitor from a bygone era?","publication_year":2015,"publication_date":"2015-10-01","ids":{"openalex":"https://openalex.org/W1940324115","doi":"https://doi.org/10.2147/dddt.s52787","mag":"1940324115","pmid":"https://pubmed.ncbi.nlm.nih.gov/26508839","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4610796"},"language":"en","primary_location":{"id":"doi:10.2147/dddt.s52787","doi":"https://doi.org/10.2147/dddt.s52787","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s52787","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27548","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=27548","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087923582","display_name":"Sai\u2010Hong Ignatius Ou","orcid":"https://orcid.org/0000-0002-1764-4975","observed_orcids":["https://orcid.org/0000-0002-1764-4975"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]},{"id":"https://openalex.org/I4390039238","display_name":"UC Irvine Chao Family Comprehensive Cancer Center","ror":"https://ror.org/05gzqy922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sai-Hong Ou","raw_affiliation_strings":["Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA","institution_ids":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032293215","display_name":"Ross Andrew Soo","orcid":"https://orcid.org/0000-0002-3053-3997","observed_orcids":["https://orcid.org/0000-0002-3053-3997"]},"institutions":[{"id":"https://openalex.org/I4210103786","display_name":"National University Cancer Institute, Singapore","ror":"https://ror.org/025yypj46","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210103786","https://openalex.org/I4210150261"]},{"id":"https://openalex.org/I4210150261","display_name":"National University Health System","ror":"https://ror.org/05tjjsh18","country_code":"SG","type":"education","lineage":["https://openalex.org/I165932596","https://openalex.org/I4210150261"]},{"id":"https://openalex.org/I4405277804","display_name":"Cancer Science Institute of Singapore","ror":"https://ror.org/03yky5015","country_code":"SG","type":"facility","lineage":["https://openalex.org/I4405277804"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Ross Soo","raw_affiliation_strings":["National University Health System and Cancer Science Institute of Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National University Health System and Cancer Science Institute of Singapore, Singapore","institution_ids":["https://openalex.org/I4210103786","https://openalex.org/I4210150261","https://openalex.org/I4405277804"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5087923582"],"corresponding_institution_ids":["https://openalex.org/I204250578","https://openalex.org/I4390039238"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.6555,"has_fulltext":true,"cited_by_count":29,"citation_normalized_percentile":{"value":0.51480051,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"9","issue":null,"first_page":"5641","last_page":"5641"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dacomitinib","display_name":"dacomitinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9290000200271606},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/egfr-mutant-non-small-cell-lung-cancer","display_name":"EGFR-mutant non-small cell lung cancer","score":0.875},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.871999979019165},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.9559999704360962},{"id":"https://openalex.org/keywords/third-generation-egfr-tki","display_name":"third-generation EGFR-TKI","score":0.9649999737739563},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.796999990940094},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9369999766349792},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.8190000057220459},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6669999957084656}],"concepts":[{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.9085524678230286},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.8189043402671814},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.7798618078231812},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7321947813034058},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6553280353546143},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5948151350021362},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5684017539024353},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4947914481163025},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45735684037208557},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4124099910259247},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.40965938568115234},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38086825609207153},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36850178241729736}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018579","descriptor_name":"Patient Selection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052999","descriptor_name":"Quinazolinones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052999","descriptor_name":"Quinazolinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.2147/dddt.s52787","doi":"https://doi.org/10.2147/dddt.s52787","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s52787","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27548","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4610796","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4610796","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Des Devel Ther","raw_type":"Text"},{"id":"pmid:26508839","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26508839","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug design, development and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:dovepress.com/24160","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/dacomitinib-in-lung-cancer-a-ldquolost-generationrdquo-egfr-tyrosine-k-peer-reviewed-article-DDDT","pdf_url":"https://www.dovepress.com/dacomitinib-in-lung-cancer-a-ldquolost-generationrdquo-egfr-tyrosine-k-peer-reviewed-article-DDDT","source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Review"},{"id":"pmh:oai:doaj.org/article:a0e918c867f94be38e8aa6fdc2130b08","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/a0e918c867f94be38e8aa6fdc2130b08","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drug Design, Development and Therapy, Vol 2015, Iss default, Pp 5641-5653 (2015)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.2147/dddt.s52787","doi":"https://doi.org/10.2147/dddt.s52787","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s52787","pdf_url":"https://www.dovepress.com/getfile.php?fileID=27548","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1940324115.pdf","grobid_xml":"https://content.openalex.org/works/W1940324115.grobid-xml"},"referenced_works_count":57,"referenced_works":["https://openalex.org/W1975275422","https://openalex.org/W1980497534","https://openalex.org/W1984004254","https://openalex.org/W1995644960","https://openalex.org/W2003898299","https://openalex.org/W2043696829","https://openalex.org/W2072120492","https://openalex.org/W2076178766","https://openalex.org/W2088540000","https://openalex.org/W2096198395","https://openalex.org/W2097026987","https://openalex.org/W2097699101","https://openalex.org/W2100912832","https://openalex.org/W2102743085","https://openalex.org/W2105832080","https://openalex.org/W2106140212","https://openalex.org/W2110841878","https://openalex.org/W2111662961","https://openalex.org/W2112098753","https://openalex.org/W2113508099","https://openalex.org/W2126177831","https://openalex.org/W2129360604","https://openalex.org/W2131407638","https://openalex.org/W2132157071","https://openalex.org/W2132870547","https://openalex.org/W2133149289","https://openalex.org/W2134978639","https://openalex.org/W2137005514","https://openalex.org/W2138297714","https://openalex.org/W2139236349","https://openalex.org/W2140980839","https://openalex.org/W2142247783","https://openalex.org/W2144180913","https://openalex.org/W2149654081","https://openalex.org/W2152905269","https://openalex.org/W2153477391","https://openalex.org/W2154149901","https://openalex.org/W2156353875","https://openalex.org/W2158043872","https://openalex.org/W2160336497","https://openalex.org/W2160982674","https://openalex.org/W2161152839","https://openalex.org/W2161821474","https://openalex.org/W2166084034","https://openalex.org/W2170030318","https://openalex.org/W2171139285","https://openalex.org/W2307503596","https://openalex.org/W2311237181","https://openalex.org/W2315455232","https://openalex.org/W2325481887","https://openalex.org/W2329759709","https://openalex.org/W2337494164","https://openalex.org/W2462237620","https://openalex.org/W2474212125","https://openalex.org/W2572174216","https://openalex.org/W2623429993","https://openalex.org/W4235389138"],"related_works":["https://openalex.org/W2972023046","https://openalex.org/W2325071936","https://openalex.org/W2940838211","https://openalex.org/W2604698167","https://openalex.org/W3154133150","https://openalex.org/W1983521375","https://openalex.org/W2578736186","https://openalex.org/W2940369499","https://openalex.org/W2965705506","https://openalex.org/W2627001967"],"abstract_inverted_index":{"EGFR":[0,21,53,80,97,104,113,115,215,230,235,245,272],"tyrosine-kinase":[1],"inhibitors":[2],"(TKIs)":[3],"have":[4,247],"now":[5,126],"been":[6,125,127],"firmly":[7],"established":[8],"as":[9,185,201,282],"the":[10,59,65,75,88,94,110,130,147,160,202,206,252,267,275,289,295],"first-line":[11,131,186,283],"treatment":[12,132,187,284,296],"for":[13,70,129,205],"non-small-cell":[14],"lung":[15],"cancer":[16],"(NSCLC)":[17],"patients":[18,50,193],"harboring":[19],"activating":[20,96],"mutations,":[22],"based":[23],"on":[24],"seven":[25],"prospective":[26],"randomized":[27,166,177],"Phase":[28,153,156,167],"III":[29,157,168],"trials.":[30],"However,":[31],"despite":[32],"significantly":[33],"improved":[34,39],"overall":[35],"response":[36],"rate":[37],"and":[38,114,198,223,227,241,255,258,274,280],"median":[40],"progression-free":[41],"survival":[42],"when":[43],"compared":[44],"to":[45,58,72,86,93,107,140,155,183,300],"platinum-doublet":[46],"chemotherapy,":[47],"EGFR-mutant":[48,134,191,286],"NSCLC":[49,135,192,287,298],"treated":[51],"with":[52,64],"TKIs":[54,81,216,246,273],"invariably":[55],"progress":[56],"due":[57],"emergence":[60],"of":[61,74,133,150,188,209,243,270,277,285,292,297],"acquired":[62],"resistances,":[63],"gatekeeper":[66],"T790M":[67,89,231],"mutation":[68],"accounting":[69],"up":[71],"60%":[73],"resistance":[76],"mechanisms.":[77],"Second-generation":[78],"irreversible":[79],"were":[82],"developed":[83],"in":[84,91,211,237,263,294],"part":[85],"inhibit":[87,108,229],"mutation,":[90],"addition":[92],"common":[95],"mutations.":[98],"Dacomitinib":[99],"is":[100,118],"one":[101],"such":[102],"second-generation":[103,120],"TKI":[105,122],"designed":[106],"both":[109],"wild-type":[111],"(WT)":[112],"T790M.":[116],"Afatinib":[117],"another":[119,175],"EGR":[121],"that":[123,225],"has":[124],"approved":[128,262],"patients,":[136,288],"while":[137],"dacomitinib":[138,151,182,210,293],"continues":[139],"undergo":[141],"clinical":[142,148,239],"evaluation.":[143],"We":[144],"will":[145,194,199,259],"review":[146],"development":[149,269],"from":[152,174],"I":[154],"trials,":[158],"including":[159],"two":[161],"recently":[162],"published":[163],"negative":[164],"large-scale":[165,176],"trials":[169],"(ARCHER":[170,179],"1009,":[171],"NCIC-BR-26).":[172],"Results":[173],"trial":[178,204],"1050)":[180],"comparing":[181],"gefitinib":[184],"advanced":[189],"treatment-na\u00efve":[190],"soon":[195],"be":[196,261,301],"available":[197],"serve":[200],"lynchpin":[203],"potential":[207],"approval":[208,276],"NSCLC.":[212],"Meanwhile,":[213],"third-generation":[214,271],"(eg,":[217],"CO-1686":[218],"[rociletinib],":[219],"AZ9291,":[220],"HM61713,":[221],"EGF816,":[222],"ASP8273)":[224],"preferentially":[226],"potently":[228],"but":[232],"not":[233],"WT":[234],"are":[236],"full-scale":[238],"development,":[240],"some":[242],"these":[244],"received":[248],"\"breakthrough\"":[249],"designation":[250],"by":[251],"US":[253],"Food":[254],"Drug":[256],"Administration":[257],"likely":[260],"late":[264],"2015.":[265],"Given":[266],"rapid":[268],"gefitinib,":[278],"erlotinib,":[279],"afatinib":[281],"future":[290],"role":[291],"seems":[299],"limited.":[302]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}